Showing 1071-1080 of 1148 results for "".
- Nuplazid Safety and Efficacy As Treatment for Neuropsychiatric Symptoms in Frail Older Adults with Neurodegenerative Disease Reportedhttps://practicalneurology.com/news/nuplazid-safety-and-efficacy-as-treatment-for-neuropsychiatric-symptoms-in-frail-older-adults-with-neurodegenerative-disease-reported/2470606/Results from a 52-week, multicenter, phase 3b, open-label extension study (NCT03623321) revealed that Nuplazid (pimavanserin; Acadia Pharmaceuticals, San Diego, CA) was effective and generally safe as a treatment for neuropsychiatric symptoms in frail older adults with neurodegenerative
- New FDA-Cleared Software Update Enhances MRI Analysis for ARIA Detectionhttps://practicalneurology.com/news/new-fda-cleared-software-update-enhances-mri-analysis-for-aria-detection/2470568/NeuroQuant v5.0 (Cortechs.ai, San Diego, CA), the latest update to NeuroQuant (Cortechs.ai, San Diego, CA) neuroimaging analysis software, has received Food and Drug Administration (FDA) 510(k) clearance. The update enables the identification and evaluation of focal brain lesions in MRI images, w
- Investigational Therapy for Facioscapulohumeral Muscular Dystrophy Shows Promise According to Avidity Bioscienceshttps://practicalneurology.com/news/investigational-therapy-for-facioscapulohumeral-muscular-dystrophy-shows-promise-according-to-avidity-biosciences/2470511/Initial 4-month results from the phase 1/2 FORTITUDE clinical trial (NCT05747924) reveal that treatment of people with facioscapulohumeral muscular dystrophy (FSHD) using AOC 1020 (delpacibart braxlosiran [del-brax]; Avidity Biosciences, San Diego, CA) is associated with functional improvement an
- AHS Celebrates Award Winners at 66th Annual Scientific Meetinghttps://practicalneurology.com/news/ahs-celebrates-annual-award-winners-at-66th-annual-scientific-meeting/2470502/Twenty-four individuals who have contributed to the field of headache and migraine were recognized by the American Headache Society (AHS) at the 66th Annual Scientific Meeting held in San Diego, CA. Awards were given in a variety of categories to acknowledge outstanding publications, researc
- Lifestyle Changes Improved Cognition, Function, Aβ Biomarkers in People with Early Alzheimer Disease According to RCThttps://practicalneurology.com/news/lifestyle-changes-improved-cognition-function-av-biomarkers-in-people-with-early-alzheimer-disease-according-to-rct/2470499/Lifestyle changes, including diet, exercise, stress management, and participation in support groups, were associated with improved cognition and function in people with mild cognitive impairment (MCI) or early dementia due to Alzheimer disease (AD). People who received usual care showed no improv
- Synapse-Generating Small Molecule for ALS Receives Nod from FDA for Clinical Trialhttps://practicalneurology.com/news/synapse-generating-small-molecule-for-als-receives-nod-from-fda-for-clinical-trial/2470486/The Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for SPG302 (Spinogenix, San Diego, CA) for evaluation as a potential treatment for people with amyotrophic lateral sclerosis (ALS) as a once-daily pill. The safety, tolerability, and pharmacokinetics
- Ingrezza Treatment Associated with Sustained Improvements in Patients with Tardive Dyskinesiahttps://practicalneurology.com/news/ingrezza-treatment-associated-with-sustained-improvements-in-patients-with-tardive-dyskinesia/2470477/Results of a post hoc analysis of the KINECT-4 study showed that the majority of participants with tardive dyskinesia (TD) who completed 48 weeks of once-daily Ingrezza (valbenazine; Neurocrine Biosciences, San Diego, CA) treatment experienced clinically meaningful and sustained TD improvements.
- FDA Grants Breakthrough Therapy Designation to Delpacibart Etedesiran for Myotonic Dystrophy Type 1https://practicalneurology.com/news/fda-grants-breakthrough-therapy-designation-to-delpacibart-etedesiran-for-myotonic-dystrophy-type-1/2470471/Delpacibart etedesiran (del-desiran/AOC 1001; Avidity Biosciences, San Diego, CA) has been granted Breakthrough Therapy designation by the Food and Drug Administration (FDA) as an investigational treatment for myotonic dystrophy type 1 (DM1). Delpacibart etedesiran was previously granted Orphan D
- FDA Approves Ingrezza Sprinkle Formulation for Tardive Dyskinesia or Chorea Associated with Huntington Diseasehttps://practicalneurology.com/news/fda-approves-ingrezza-sprinkle-formulation-for-tardive-dyskinesia-or-chorea-associated-with-huntington-disease/2470463/The Food and Drug Administration (FDA) has approved a new sprinkle formulation of Ingrezza (valbenazine; Neurocrine Biosciences, San Diego, CA) for patients with tardive dyskinesia (TD) or chorea associated with Huntington disease (HD). The oral granule capsules (available in 40 mg, 60 mg, and 80
- Long-Term Data from LILAC-2 Study of Daybue for Rett Syndrome Reportedhttps://practicalneurology.com/news/long-term-data-from-lilac-2-study-of-daybue-for-rett-syndrome-reported/2470362/People who used Daybue (trofinetide; Acadia Pharmaceuticals, San Diego, CA) on a long-term basis showed improvements in the core symptoms of Rett syndrome, according to results of the 104-week LILAC-2 (NCT04776746) open-label extension (OLE) study. The safety profile results found in this OLE stu